Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Maxim Pimpkin, MD
Tango Therapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chu de Brest
Brest, France
Jean-Philippe Metges, MDRecruiting - Centre Berard Leon
Lyon, France
Philippe Cassier, MDRecruiting - Institut de Cancerologie de L'Ouest - Hôpital Saint Herblain - Ppds
Saint-Herblain, France
Ludovic Doucet, MD, MScRecruiting - Institute Gustav Roussy
Villejuif, France
Kaissa Ouali, MDRecruiting
- Vall D'Hebron Barcelona Hospital
Barcelona, Catalonia, Spain
Irene Brana, MDRecruiting - Hospital Hm Nou Delfos
Barcelona, Spain
Tatiana Hernandez Guerrero, MDRecruiting - Ico L'Hospitalet - Hospital Duran I Reynals
Barcelona, Spain
Mariona Calvo Campos, MDRecruiting - Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
Victor Moreno Garcia, MDRecruiting - Hospital de Sanchinarro
Madrid, Spain
Emiliano Calvo Aller, MDRecruiting - Hospital Universitario Virgen de la Victoria
Málaga, Spain
Javier Garcia-Corbacho, MDRecruiting - Hospital Universitario Virgen del Rocio
Seville, Spain
Alejandro Falcon, MDRecruiting
- Stanford University
Palo Alto, California, United States
Christopher ChenRecruiting - Grand Valley Oncology
Grand Junction, Colorado, United States
Jonathan King, MDRecruiting - Florida Cancer Specialists & Research Institute
Lake Mary, Florida, United States
Completed - Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Jose Lutzky, MDRecruiting - University Chicago Medicine
Chicago, Illinois, United States
Hedy Kindler, MDRecruiting - Carle Cancer Center
Urbana, Illinois, United States
Tammay Sahai, MDRecruiting - Midwestern Regional Medical Center, City of Hope Chicago
Zion, Illinois, United States
Evan Pisick, MDRecruiting - Dana Farber Cancer Institute
Boston, Massachusetts, United States
Candace Haddox, MDRecruiting - Massachusetts General Hospital
Boston, Massachusetts, United States
Ibiayi Dagogo-Jack, MDRecruiting - Henry Ford Cancer Center
Detroit, Michigan, United States
Amy Weise, DORecruiting - New York University Langone Health
New York, New York, United States
Salman Punekar, MDRecruiting - Sarah Cannon Tennessee Oncology
Nashville, Tennessee, United States
David Spigel, MDRecruiting - the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Jordi Rodon Ahnert, MDRecruiting - Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States
Vaia Florou, MD, MSRecruiting - Next Oncology Virginia
Fairfax, Virginia, United States
Alexander Spira, MD, PhDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 May 2023
- Primary completion
- 31 May 2026
- Completion
- 30 Sept 2026
- Last update posted
- 21 Apr 2026
- Registered enrollment
- 225
- Registry id
- NCT05732831
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.